Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
|Title:||Ibudilast reduces oxaliplatin-induced tactile allodynia and cognitive impairments in rats|
|Citation:||Behavioural Brain Research, 2017; 334:109-118|
|Ian N. Johnstona, Manuela Tana, Jacob Caoa, Antigone Matsosa, Daniel R.L. Forresta, Emily Sia, Joanna E. Fardella, Mark R. Hutchinsonc|
|Abstract:||Chemotherapy can cause serious neurotoxic side effects, such as painful peripheral neuropathies and disabling cognitive impairments. Four experiments examined whether Ibudilast, a clinically approved neuroimmune therapy, would reduce tactile allodynia and memory impairments caused by oxaliplatin in laboratory rats. Rats received an intraperitoneal injection of oxaliplatin (6mg/kg i.p.) or vehicle and were assessed for tactile allodynia 3 or 5days after injection, memory impairments in the novel object and novel location recognition tests 10-12days after injection, and fear conditioning 14days after injection. Ibudilast (7.5mg/kg) or vehicle was administered prior to oxaliplatin (Experiments 1 and 3) or prior to behavioural testing (Experiments 2 and 4). Ibudilast treatment prior to oxaliplatin prevented the development of tactile allodynia and memory impairments. Ibudilast treatment prior to behavioural testing reduced oxaliplatin-induced tactile allodynia, memory impairments, and impaired renewal of fear conditioning. These results suggest that Ibudilast could be an effective treatment against oxaliplatin-induced neuropathies and cognitive impairments.|
|Keywords:||Oxaliplatin; chemotherapy; neuropathic pain; memory impairment; ibudilast|
|Rights:||© 2017 Elsevier B.V. All rights reserved.|
|Appears in Collections:||Medicine publications|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.